LitCovid-sentences  

PMC:7195088 / 26137-29724 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T194 136-260 Sentence denotes Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting).
T195 261-458 Sentence denotes Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months).
T196 459-545 Sentence denotes • Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients.
T197 546-597 Sentence denotes Double-blind RCT (NCT04328961, not yet recruiting).
T198 598-666 Sentence denotes Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days).
T199 667-803 Sentence denotes • Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19.
T200 804-853 Sentence denotes Open-label RCT (NCT04332094, not yet recruiting).
T201 854-1081 Sentence denotes Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19.
T202 1082-1131 Sentence denotes Open-label RCT (NCT04330586, not yet recruiting).
T203 1132-1205 Sentence denotes Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14.
T204 1206-1332 Sentence denotes • Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors.
T205 1333-1384 Sentence denotes Double-blind RCT (NCT04330495, not yet recruiting).
T206 1385-1595 Sentence denotes Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks).
T207 1596-1704 Sentence denotes • Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk.
T208 1705-1756 Sentence denotes Double-blind RCT (NCT04328467, not yet recruiting).
T209 1757-1819 Sentence denotes Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks).
T210 1820-1932 Sentence denotes • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19.
T211 1933-1984 Sentence denotes Double-blind RCT (NCT04328285, not yet recruiting).
T212 1985-2002 Sentence denotes Primary endpoint:
T213 2003-2091 Sentence denotes Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months).
T214 2092-2213 Sentence denotes • Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households.
T215 2214-2257 Sentence denotes Double-blind RCT (NCT04308668, recruiting).
T216 2258-2405 Sentence denotes Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14.
T217 2406-2521 Sentence denotes • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19.
T218 2522-2580 Sentence denotes Open-label adaptive RCT (NCT04321616, not yet recruiting).
T219 2581-2651 Sentence denotes Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks).
T220 2652-2763 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19.
T221 2764-2825 Sentence denotes Double-blind, adaptive RCT (NCT04328012, not yet recruiting).
T222 2826-2902 Sentence denotes Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days).
T223 2903-3061 Sentence denotes • Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19.
T224 3062-3111 Sentence denotes Open-label RCT (NCT04332835, not yet recruiting).
T225 3112-3291 Sentence denotes Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28.
T226 3292-3461 Sentence denotes • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19.
T227 3462-3515 Sentence denotes Double-blind, adaptive RCT (NCT04315948, recruiting).
T228 3516-3587 Sentence denotes Primary endpoint: severity rating on a 7-point ordinal scale at day 15.